BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 26, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Dec. 5, 2006
View Archived Issues
Onyx's Shares Drop On Top-Line Results Of Nexavar In Melanoma
A Phase III failure of Nexavar in advanced melanoma thumped Onyx Pharmaceuticals Inc.'s stock by more than 30 percent Monday. (BioWorld Today)
Read More
Pfizer's Torcetrapib Failure Boosts Isis Market Chances
Read More
FM-VP4 Misses Main Endpoint; Forbes MediTech Falls By Half
Read More
Sangamo Gets VEGF-ZFP Rights From Edwards In Angiogenesis
Read More
Micromet Shares Take Ride On $10M Serono Payment
Read More
Other News To Note
Read More
Clinic Roundup
Read More